3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: Considerations in the renal failure patient

Current Opinion in Nephrology and Hypertension

Volumn 11, Issue 2, 2002, Pages 123-133

  Sica, Domenic A ^a   Gehr, Todd W B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN A; ERYTHROMYCIN; FLUCONAZOLE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TACROLIMUS; WARFARIN;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; HUMAN; KIDNEY FAILURE; MUSCLE INJURY; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; TREATMENT INDICATION;

CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE; RHABDOMYOLYSIS; RISK FACTORS;

EID: 0036189904     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200203000-00001     Document Type: Review

References (126)

1. Withdrawal of cerivastatin from the world market
2. Bayer faces potential fine over cholesterol lowering drug
3. Bayer recall spurs Europe to wide review
4. Rhabdomyolysis and statin therapy: Relevance to the elderly
5. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease
6. Lipid abnormalities in end stage renal disease
7. Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease
8. Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment
9. Dyslipidemia in peritoneal dialysis: Relation to dialytic variables
10. Lipid abnormalities in renal disease
11. Metabolic abnormalities in renal transplant recipients: Risk factors and predictors of chronic graft dysfunction?
12. Cholesterol and mortality: 30 Years of follow-up from the Framingham study
13. Kidney transplant recipients who die with functioning grafts: Serum creatinine level and cause of death
14. Sudden cardiac death in cardiac transplant recipients
15. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis
16. Lipids and the kidney
17. Statins and progressive renal disease
18. Hyperlipidaemia in renal transplantation: Risk factor for long-term graft outcome
19. Risk factors predicting chronic rejection of renal allografts
20. Importance of hyperlipidaemia and therapy in renal patients
21. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis: Results from a prospective study
22. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency
23. Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter
24. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients
25. Optimizing medical management of patients with pre-end-stage renal disease
26. The rationale for early management of chronic renal insufficiency
27. Renoprotection: One or many therapies?
28. Recent advances in statins and the kidney
29. Lipid-lowering therapy in membranous nephropathy
30. Effect of HMG-CoA reductase inhibitors on chronic allograft rejection
31. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial
32. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy
33. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients
34. Lipid-lowering therapy in patients with renal disease
35. Simvastatin in nephrotic syndrome
36. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
37. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
38. HMG-CoA reductase inhibitors in the prevention of stroke
39. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
40. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other nontraditional cardiac risk factors
41. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis
42. The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: A double-blind, placebo-controlled trial in patients with ESRD
43. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis
44. Synthetic statins: More data on newer lipid-lowering agents
45. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans
46. Clinical pharmacokinetics of pravastatin: Mechanisms of pharmacokinetic events
47. Clinical pharmacokinetics of fluvastatin
48. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences
49. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias
50. Clinical pharmacokinetics of cerivastatin
51. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins)
52. In vitro metabolism of simvastatin in humans [SBT]: Identification of metabolizing enzymes and effect of the drug on hepatic P450s
53. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
54. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin
55. Metabolism of the new immunosuppressor cyclosporine G by human liver cytochromes P450
56. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs
57. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients
58. CYP3A gene expression in human gut epithelium
59. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects
60. Tissue-selective uptake of pravastatin in rats: Contribution of a specific carrier-mediated uptake system
61. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment
62. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterel reduction of atorvastatin
63. The pharmacokinetics of pravastatin in patients on chronic hemodialysis
64. Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors
65. 14C-lovastatin in chronic renal failure
66. Clinically relevant differences between the statins: Implications for therapeutic selection
67. Decreased in vivo metabolism of drugs in chronic renal failure
68. Downregulation of hepatic cytochrome P450 in chronic renal failure
69. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs
70. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors
71. The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins
72. Rhabdomyolysis and HMG-CoA reductase inhibitors
73. HMG-CoA reductase inhibitors and myotoxicity
74. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
75. Rhabdomyolysis associated with lovastatin and erythromycin use
76. Lovastatin and rhabdomyolysis
77. Drug-interactioninduced rhabdomyolysis
78. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin
79. Oytochrome P 450 3A4: Regulation and role in drug metabolism
80. Rhabdomyolysis and acute renal failure secondary to statins
81. Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure
82. Rhabdomyolysis due to simvastatin in a transplant patient: Are some statins safer than others?
83. Short-term effect of atorvastatin in hypercholesterolaemic renal-transpiant patients unresponsive to other statins
84. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine
85. Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporine
86. Postoperative management following heart transplantation
87. Severe rhabdomyolysis associated with tacrolimus
88. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
89. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
90. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance
91. Statin-fibrate combination therapy
92. Cerivastatin, and gemfibrozilassociated rhabdomyolysis
93. Fatal rhabdomyolysis caused by lipidlowering therapy
94. Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: Is the interaction predictable?
95. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin
96. Lovastatin, nicotinic acid, and rhabdomyolysis
97. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia
98. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin
99. Polymyositis associated with simvastatin
100. Pravastatin-associated inflammatory myopathy
101. Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease
102. Lovastatin-induced acute rhabdomyolysis
103. Use of statins and fibrates in hyperlipidemic patients with neuromuscular disorders
104. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological, electrophysiological, and biochemical study
105. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin
106. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia
107. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
108. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
109. Updated clinical safety experience with fluvastatin
110. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin
111. Efficacy and long-term adverse effect pattern of lovastatin
112. Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects
113. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up
114. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia
115. Efficacy and tolerability of fluvastatin extended-release delivery system: A pooled analysis
116. Lovastatin and elevated creatine kinase: Results of rechallenge
117. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day
118. Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: Focus on drug interactions
119. HMG-CoA reductase inhibitorinduced myopathy in the rat: Cyclosporine A interaction and mechanism studies
120. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes
121. Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors
122. A review of clinical trials comparing HMG-CoA reductase inhibitors
123. Consensus statement: Role of therapy with 'statins' in patients with hypertriglyceridemia